Gene-gene and gene-environment interactions in interferon therapy for chronic hepatitis C.

INTRODUCTION In studies of pharmacogenomics, it is essential to address gene-gene and gene-environment interactions to describe complex traits involving pharmacokinetic and pharmacodynamic mechanisms. In this work, our goal is to detect gene-gene and gene-environment interactions resulting from an analysis of chronic hepatitis C patients' clinical factors including SNPs, viral genotype, viral load, age and gender. MATERIALS & METHODS We collected blood samples from 523 chronic hepatitis C patients who had received interferon and ribavirin combination therapy. Based on the treatment strategy for chronic hepatitis C patients, we focused our search for candidate genes involved in pathways related to interferon signaling and immunomodulation. To investigate gene-gene and gene-environment interactions, we implemented an artificial neural network-based method for identifying significant interactions between clinical factors with the fivefold crossvalidation method and permutation tests. The artificial neural network model was trained by an algorithm with an adaptive momentum and learning rate. RESULTS A total of 20 SNPs were selected from six candidate genes including adenosine deaminase-RNA-specific (ADAR), caspase 5 (CASP5), interferon consensus sequence binding protein 1 (ICSBP1), interferon-induced protein 44 (IFI44), phosphoinositide-3-kinase catalytic gamma polypeptide (PIK3CG), and transporter 2 ATP-binding cassette subfamily B (TAP2) genes. By applying our artificial neural network-based approach, IFI44 was found in the significant two-locus, three-locus and four-locus gene-gene effect models, as well as in the significant two-factor and three-factor gene-environment effect models. Furthermore, viral genotype remained in the best two-factor, three-factor and four-factor gene-environment models. These results support the hypothesis that IFI44 and viral genotype may play a role in the pharmacogenomics of interferon treatment. In addition, our approach identified a panel of ten clinical factors that may be more significant than the others for further study. CONCLUSION We demonstrated that our artificial neural network-based approach is a promising method to assess the gene-gene and gene-environment interactions for interferon and ribavirin combination treatment in chronic hepatitis C patients by using clinical factors such as SNPs, viral genotype, viral load, age and gender.

[1]  M. Drescher,et al.  [Therapy of hepatitis]. , 1953, Wiener klinische Wochenschrift.

[2]  Sims Jl.  Management of hepatitis. , 1969, Wisconsin medical journal.

[3]  Geoffrey E. Hinton,et al.  Learning internal representations by error propagation , 1986 .

[4]  N. Kitamura,et al.  Induction of the human gene for p44, a hepatitis-C-associated microtubular aggregate protein, by interferon-alpha/beta. , 1994, European journal of biochemistry.

[5]  P. Marcellin,et al.  Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C , 1995, Hepatology.

[6]  P. Simmonds.  Variability of hepatitis C virus , 1995, Hepatology.

[7]  K. Grünewald,et al.  Detection of hepatitis C viral sequences in serum by 'nested' polymerase chain reaction (PCR) and a commercial single-round PCR assay. , 1995, Clinical and diagnostic virology.

[8]  Christopher M. Bishop,et al.  Neural networks for pattern recognition , 1995 .

[9]  J. Hoofnagle,et al.  Therapy of Hepatitis C , 1995, Seminars in liver disease.

[10]  Ding‐Shinn Chen,et al.  Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. , 1996, Gastroenterology.

[11]  Jenq-Neng Hwang,et al.  Neural networks for intelligent multimedia processing , 1998 .

[12]  M. Hijikata,et al.  Identification of a Single Nucleotide Polymorphism in the MxA Gene Promoter (G/T at nt –88) Correlated with the Response of Hepatitis C Patients to Interferon , 2000, Intervirology.

[13]  R. Kaslow,et al.  Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection , 2001, Hepatology.

[14]  B. Walker,et al.  Hepatitis C virus infection. , 2001, The New England journal of medicine.

[15]  Trevor Hastie,et al.  The Elements of Statistical Learning , 2001 .

[16]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[17]  R. Chapman,et al.  Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues. , 2001, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[18]  J. Vierling,et al.  Viral, host and interferon‐related factors modulating the effect of interferon therapy for hepatitis C virus infection , 2001, Journal of viral hepatitis.

[19]  N. Key,et al.  Hepatitis C in adults and adolescents with hemophilia: A randomized, controlled trial of interferon alfa‐2b and ribavirin , 2002, Hepatology.

[20]  N. Hayashi,et al.  A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C , 2002, Journal of viral hepatitis.

[21]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[22]  J. Pawlotsky.  Use and interpretation of virological tests for hepatitis C , 2002, Hepatology.

[23]  A. Alberti,et al.  Management of hepatitis C. , 2003, Journal of hepatology.

[24]  D Curtis,et al.  Assessing Optimal Neural Network Architecture for Identifying Disease‐associated Multi‐marker Genotypes using a Permutation Test, and Application to Calpain 10 Polymorphisms Associated with Diabetes , 2003, Annals of human genetics.

[25]  M. Manns,et al.  Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.

[26]  P. Ferenci.  Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. , 2003, The Journal of antimicrobial chemotherapy.

[27]  R. Erb,et al.  Introduction to Backpropagation Neural Network Computation , 1993, Pharmaceutical Research.

[28]  R. Cozzolongo,et al.  Artificial neural networks for the prediction of response to interferon plus ribavirin treatment in patients with chronic hepatitis C. , 2004, Current pharmaceutical design.

[29]  Chris S. Haley,et al.  Epistasis: too often neglected in complex trait studies? , 2004, Nature Reviews Genetics.

[30]  Alison A Motsinger,et al.  Multifactor dimensionality reduction for detecting gene-gene and gene-environment interactions in pharmacogenomics studies. , 2005, Pharmacogenomics.

[31]  M. Daly,et al.  Genome-wide association studies for common diseases and complex traits , 2005, Nature Reviews Genetics.

[32]  E R Martin,et al.  Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. , 2005, American journal of human genetics.

[33]  B. Bacon,et al.  Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. , 2005, The American journal of managed care.

[34]  L. Sidiropoulos,et al.  The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha‐2b plus ribavirin treatment of naïve and nonresponder chronic hepatitis C patients , 2005, Journal of viral hepatitis.

[35]  P. Marcellin,et al.  Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α‐2a (40 kd)/ribavirin therapy , 2006, Hepatology.

[36]  H. vanSoest,et al.  Hepatitis C: changing genotype distribution with important implications for patient management. , 2006 .

[37]  Eugene Lin,et al.  An artificial neural network approach to the drug efficacy of interferon treatments. , 2006, Pharmacogenomics.

[38]  Ding-Shinn Chen,et al.  Genetic predisposition of responsiveness to therapy for chronic hepatitis C. , 2006, Pharmacogenomics.

[39]  Jerzy K. Kulski,et al.  Blood pressure QTLs identified by genome-wide linkage analysis and dependence on associated phenotypes , 2002 .

[40]  E. Lin,et al.  Pattern-recognition techniques with haplotype analysis in pharmacogenomics. , 2007, Pharmacogenomics.

[41]  S. Hadjitodorov,et al.  Empirical versus mechanistic modelling: Comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetic relationships of a homologous series of barbiturates , 1999, AAPS PharmSci.